Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Osteoporosis Prevention in Early Breast Cancer Patients Receiving Letrozole
NCT00376740Phase 3Completed
- Sponsor
- Soroka University Medical Center
- Start
- Sep 2005
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Soroka University Medical Center. Primary endpoints: Bone Mineral Density, Bone events and 2 more. Started Sep 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00376740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376740.